Cannabis in inflammatory bowel disease: a narrative summary
DOI:
https://doi.org/10.22516/25007440.407Keywords:
cannabis, ulcerative colitis, Crohn´s disease, inflammatory bowel disease, medicinal marijuanaAbstract
Introduction: Although cannabinoids have been used for several years, only recently have their mechanisms of action and therapeutic targets been described. Alterations in the endocannabinoid system have been observed in various diseases and conditions such as pain, inflammation, autoimmune diseases and various specific disorders. Inflammatory bowel disease groups two chronic idiopathic conditions with uncertain pathogeneses in which deregulation of the immune system plays an important role. Alternative treatments need to be developed for these patients since only a minority of patients achieve disease remission. Our goal is to review recent evidence related to the use of cannabis to treat ulcerative colitis and Crohn’s disease.
Methods: This is a focused narrative review based on searches of Pubmed and Embase. Relevant articles have been reviewed and summarized in narrative form.
Results: The two main components of cannabis, CBD and THC, have been extensively studied, and their anti-inflammatory and antinociceptive effects have been tested. The effects of these components for control of the symptoms of ulcerative colitis and Crohn’s disease have been widely described. However, high quality studies are needed to continue evaluating the efficacy and safety of cannabis use in patients with inflammatory bowel disease.
Downloads
References
Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov. 2008;7(5):438-55. https://doi.org/10.1038/nrd2553
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta 9-tetrahydrocannabinol, cannabidiol and delta 9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. https://doi.org/10.1038/sj.bjp.0707442
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. Chem Biodivers. 2007;4(8):1678-92. https://doi.org/10.1002/cbdv.200790147
Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44(4):673-692. https://doi.org/10.1016/j.pop.2017.07.010
Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019;94(1):155-165. https://doi.org/10.1016/j.mayocp.2018.09.013
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713-25. https://doi.org/10.1056/NEJMra1102942
Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018;35(11):1746-1762. https://doi.org/10.1007/s12325-018-0795-9
Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654-664. https://doi.org/10.1038/nrgastro.2016.116
Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016;79(7):516-25. https://doi.org/10.1016/j.biopsych.2015.07.028
Battista N, Di Tommaso M, Bari M, Maccarrone M. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9. https://doi.org/10.3389/fnbeh.2012.00009
Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical cannabis: Another piece in the mosaic of autoimmunity? Clin Pharmacol Ther. 2017;101(2):230-238. https://doi.org/10.1002/cpt.568
Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci U S A. 2017;114(19):5005-5010. https://doi.org/10.1073/pnas.1612177114
Hasenoehrl C, Taschler U, Storr M, Schicho R. The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil. 2016;28(12):1765-1780. https://doi.org/10.1111/nmo.12931
de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13-27. https://doi.org/10.1038/nrgastro.2015.186
Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154(5):1001–1008. https://doi.org/10.1038/bjp.2008.177
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. https://doi.org/10.1016/S0140-6736(16)32126-2
Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon. 2018;64(2):20-57. https://doi.org/10.1016/j.disamonth.2017.07.001
Ambrose T, Simmons A. Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease? J Crohns Colitis. 2019;13(4):525-535. https://doi.org/10.1093/ecco-jcc/jjy185
Quezada SM, Briscoe J, Cross RK. Complementary and Alternative Medicine. Inflamm Bowel Dis. 2016;22(6):1523-30. https://doi.org/10.1097/MIB.0000000000000761
Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):415-429.e15. https://doi.org/10.1053/j.gastro.2016.10.004
Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, et al. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis. 2019;25(3):427-435. https://doi.org/10.1093/ibd/izy319
Fernández A, Simian D, Quera R, Flores L, Ibáñez P, Lubascher J, et al. Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile. Complement Ther Med. 2018;40:77-82. https://doi.org/10.1016/j.ctim.2018.07.016
Hoffenberg EJ, McWilliams SK, Mikulich-Gilbertson SK, Murphy BV, Lagueux M, Robbins K, et al. Marijuana Use by Adolescents and Young Adults with Inflammatory Bowel Disease. J Pediatr. 2018;199:99-105. https://doi.org/10.1016/j.jpeds.2018.03.041
Kerlin AM, Long M, Kappelman M, Martin C, Sandler RS. Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(6):1600-1604. https://doi.org/10.1007/s10620-018-5040-5
Merker AM, Riaz M, Friedman S, Allegretti JR, Korzenik J. Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(11):2309-2314. https://doi.org/10.1093/ibd/izy141
Phatak UP, Rojas-Velasquez D, Porto A, Pashankar DS. Prevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017;64(2):261-264. https://doi.org/10.1097/MPG.0000000000001474
Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: A systematic review. Autoimmun Rev. 2016;15(6):513-28. https://doi.org/10.1016/j.autrev.2016.02.008
Couch DG, Maudslay H, Doleman B, Lund JN, O’Sullivan SE. The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2018;24(4):680-697. https://doi.org/10.1093/ibd/izy014
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276-1280.e1. https://doi.org/10.1016/j.cgh.2013.04.034
Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial. Dig Dis Sci. 2017;62(6):1615-1620. https://doi.org/10.1007/s10620-017-4540-z
Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85(1):1-8. https://doi.org/10.1159/000332079
Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflamm Bowel Dis. 2018;24(4):714-724. https://doi.org/10.1093/ibd/izy002
Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(3):472-80. https://doi.org/10.1097/01.MIB.0000440982.79036.d6
Pesce M, Esposito G, Sarnelli G. Endocannabinoids in the treatment of gasytrointestinal inflammation and symptoms. Curr Opin Pharmacol. 2018;43:81-86. https://doi.org/10.1016/j.coph.2018.08.009
Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl). 2009;87(11):1111-21. https://doi.org/10.1007/s00109-009-0512-x
Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Luvone T, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001;134(3):563–570. https://doi.org/10.1038/sj.bjp.0704293
Pagano E, Capasso R, Piscitelli F, Romano B, Parisi O, Finizio S, et al. An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse. Front Pharmacol. 2016;7:341. https://doi.org/10.3389/fphar.2016.00341
Leinwand KL, Jones AA, Huang RH, Jedlicka P, Kao DJ, de Zoeten EF, et al. Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease. J Crohns Colitis. 2017 27;11(11):1369-1380. https://doi.org/10.1093/ecco-jcc/jjx096
Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol. 2012;258(2):256-67. https://doi.org/10.1016/j.taap.2011.11.005
Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl). 2008;86(8):925-36. https://doi.org/10.1007/s00109-008-0359-6
Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15(11):1678-85. https://doi.org/10.1002/ibd.20960
Jamontt JM, Molleman A, Pertwee RG, Parsons ME. The effects of Δ 9 tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol. 2010;160(3):712-723. https://doi.org/10.1111/j.1476-5381.2010.00791.x
Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis. 2011;17(8):1651–1664. https://doi.org/10.1002/ibd.21538
Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018;157:134-147. https://doi.org/10.1016/j.bcp.2018.07.048
Harvey BS, Sia TC, Wattchow DA, Smid SD. Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine. 2014;65(2):236-44. https://doi.org/10.1016/j.cyto.2013.10.006
De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One. 2011;6(12):e28159. https://doi.org/10.1371/journal.pone.0028159
Nallathambi R, Mazuz M, Ion A, Selvaraj G, Weininger S, Fridlender M, et al. Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts. Cannabis Cannabinoid Res. 2017;2(1):167–182. https://doi.org/10.1089/can.2017.0027
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
